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Abstract Plasma cholesteryl ester (CE) synthesis by lecithin 
cholesterol acyltransferase (LCAT) is activated by apolipo- 
protein (apo)A-I. We studied the effect of plasma apoA-I concen- 
tration on LCAT activation, using normal, heterozygous or 
homozygous apoA-I-deficient mice made by gene targeting. 
Plasma esterified cholesterol concentrations of mice fed chow 
diets were ordered (mean f SEM): 105 * 7 (normal)>70 f 5 
(heterozygotes) > 26 2 (homozygotes) mg/dl. Plasma free cho- 
lesterol concentrations were similar among the three genotypes. 
Endogenous LCAT activity, measured as the decrease in plasma 
free cholesterol after a 1 h incubation at 37OC, was ordered: 
44 f 3 (normal)>21 2 (heterozygotes)> 5 1 (homozygotes) 
nmol C E  formed/h per ml plasma. Using a recombinant ex- 
ogenous substrate consisting of egg yolk phospholipid, [ '*C]cho- 
lesterol, and apoA-I, C E  formation of normals and hetero- 
zygotes was similar (27.4 f 0.6 and 28.8 f 1.3 nmol/h per ml 
plasma, respectively), but was significantly less for homozygotes 
(19.2 i. 1.7 nmol/h per ml plasma). However, using a small 
unilamellar vesicle substrate particle containing phospholipid 
and [14C]cholesterol, C E  formation was ordered: 1.6 i. 0.1 
(normal) = 1.6 + 0.1 (heterozygotes)>0.6 f 0.1 (homozygotes) 
nmol/h per ml plasma; addition of apoA-I to the plasma of 
homozygous animals restored C E  formation to normal levels 
(1.6 * 0.1). C E  fatty acid analysis demonstrated that plasma 
from homozygous mice contained significantly more saturated 
and monounsaturated and fewer polyunsaturated fatty acids 
compared to normal and heterozygous mice. I We conclude 
that mice with no detectable plasma apoA-I have marked reduc- 
tions in plasma C E  concentrations (70%) and CE synthesis 
(60%) and a more saturated plasma CE fatty acid profile, which 
likely reflects an increased hepatic contribution to the plasma 
C E  pool. The decreased plasma C E  synthesis in homozygous 
apoA-I-deficient mice is primarily due to a deficiency in apoA-I 
activator protein, but is also partly the result of a decrease in 
HDL substrate particles and LCAT enzyme activity. In addi- 
tion, one half of the gene dosage of apoA-I in mice is sufficient 
for activation of plasma LCAT.-Parks, J. S., H. Li, A. K. 
Gebre, T. L. Smith, and N. Maeda. Effect of apolipoprotein 
A-I deficiency on 1ecithin:cholesterol acyltransferase activation 
in mouse plasma. J.  L+id Res. 1995. 36: 349-355. 
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Apolipoprotein A-I (apoA-I) is the major apolipopro- 
tein of plasma high density lipoproteins (HDL). It is a 
243 amino acid protein, encoded by a 1.9 kb gene contain- 
ing 4 exons and 3 introns (1, 2). ApoA-I is secreted as a 
proprotein by the liver and intestine (3, 4). The pro- 
protein (249 amino acids) is rapidly cleaved to the mature 
form (243 amino acids) after secretion into plasma (5, 6). 
The primary sequence of apoA-I consists of 6 tandem 22 
amino acid repeats, which form amphipathic helixes (7, 
8). The amphipathic alpha-helical repeats are hypothe- 
sized to play an important role in two of the major func- 
tions of apoA-I, providing structural stability to the HDL 
particle and activation of plasma 1ecithin:cholesterol acyl- 
transferase (LCAT) (9-12). 
LCAT is the major source of cholesteryl esters (CE) in 
human plasma (13). The enzyme catalyzes the hydrolysis 
of fatty acyl groups from the sn-2 position of phospho- 
lipids and the transesterification of the fatty acyl group to 
the 3-0 hydroxyl group of cholesterol to generate CE 
and lysophospholipid (14). The predominant lipopro- 
tein substrate for LCAT in vivo is HDL, which also con- 
tain the cofactor apoA-I (13, 14). Several artificial sub- 
strate particles have been used to study the cofactor 
requirement for the LCAT reaction, including recom- 
binant HDL (rHDL) and vesicles (10, 15, 16). rHDL con- 
sist of phospholipid, cholesterol, and apolipoprotein 
formed by cholate dialysis and contain both substrate 
lipids and apolipoprotein activator in a structurally stable 
discoidal particle. Small unilamellar vesicles consisting of 
phospholipid and cholesterol (but no apolipoprotein) con- 
tain substrate lipids but require the addition of activator 
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to the incubation mixture. Using these artificial sub- 
strates, investigators have shown that while other apolipo- 
proteins can activate the LCAT reaction in vitro, none is 
as effective as apoA-I (10, 17). 
Several apoA-I deficiency states have been described 
(18, 19) and although all share very low levels of plasma 
apoA-I and high density lipoproteins, they differ in clini- 
cal manifestations (18, 19). In some cases such as Tangier 
disease, plasma esterification of cholesterol appears nor- 
mal in most subjects (19). However, in other apoA-I defi- 
ciency states, endogenous cholesterol esterification in 
plasma is decreased (20, 21), as is plasma LCAT activity 
measured with an exogenous, apoA-I-containing sub- 
strate (rHDL) (21-23). These results have been extended 
by showing that plasma LCAT mass also is reduced in 
some apoA-I deficiencies (21-23). Since LCAT mass and 
cholesterol esterification rate both decrease with apoA-I 
deficiency in studies where direct measurements have 
been made, the interpretation of the data regarding the 
role of apoA-I on LCAT activation in plasma is con- 
founded. 
An alternative approach to studying LCAT activation 
by apoA-I in patients with apoA-I deficiency is to use 
animal models. However, no naturally occurring apoA-I 
deficiency state has been identified in an animal model. 
Using gene targeting methods, apoA-I-deficient mice have 
been created with low plasma HDL concentrations and 
no detectable apoA-I (24). The purpose of the present 
study was twofold: to determine plasma CE formation 
rate in vitro in apoA-I-deficient mice using defined sub- 
strate particles with or without apoA-I activator, and to 
assess the effect of apoA-I gene dosage on plasma CE for- 
mation by LCAT. 
EXPERIMENTAL PROCEDURES 
Animals 
ApoA-I-deficient mice used for this study were gener- 
ated by gene targeting in embryonic stem cells derived 
from a mouse of strain 129/01a (24, 25). Mice with 129 
genetic background were made by crossing chimeras from 
the modified embryonic stem cells to strain 1290 mice. 
Mice with C57BL/6 genetic background were made by 
crossing chimeras to strain C57BL/6J mice for seven 
generations prior to intercrossing heterozygotes. The 
mice were fed a chow diet and maintained in a tempera- 
ture controlled room with a 14-h light and 10-h dark cycle. 
After an overnight fast animals were anesthetized with 
methoxyflurane (Metofane*) for blood sampling. Blood 
was collected from the retro-orbital sinus into tubes con- 
taining 2 mM EDTA, 100 pg/ml gentamycin, and 0.046 
trypsin inhibitor units of aprotindml (final concentra- 
tion). Plasma total, free, and esterified cholesterol concen- 
trations were determined by enzymatic procedures as de- 
scribed previously (26, 27). 
Cholesterol esterification assays 
Endogenous CE formation. Endogenous CE formation was 
determined after incubation of plasma at 37OC for 1 h by 
measuring the decrease in free cholesterol using enzy- 
matic procedures (26, 27). 
rHDL substrate ussuy. CE formation also was measured 
using an exogenous substrate containing apoA-I. rHDL 
were prepared by cholate dialysis as described previously 
using egg yolk lecithin, [ 14C]cholesterol (51 mCi/mmol), 
and human apoA-I at a molar ratio of 50:2:1, respectively 
(28). ApoA-I was isolated from human plasma (29). CE 
formation was assayed using 0.2 pg (0.518 nmol; Le., ini- 
tial velocity) or 1 pg (2.6 nmol; saturation substrate con- 
centration) of rHDL [14C]cholesterol, 2% bovine serum 
albumin (BSA), 10 mM P-mercaptoethanol in 0.5 ml of 
buffer (10 mM Tris, 140 mM NaCl, 0.01% EDTA, 0.01% 
NaN3, pH 7.4). Incubations were performed for 1 h at 
37OC after addition of 2-5 pl of mouse plasma as a source 
of LCAT enzyme. The reaction was terminated by addi- 
tion of 2 ml CHC13-methanol 1:2 followed by a Bligh- 
Dyer extraction (30). The lower phase was subjected to 
thin-layer chromatography to separate free and esterified 
cholesterol. Liquid scintillation spectrometry was then 
used to quantify the amount of I4C in free and esterified 
cholesterol. Percentage CE formed was converted to nmol 
CE formedh per ml plasma. 
Vesicle substrate assay 
CE formation also was measured using vesicles con- 
taining phosphatidylcholine and [ 14C]cholesterol with no 
exogenous apoA-I. The vesicle assay tested the ability of 
mouse plasma to provide both LCAT enzyme as well as 
activator proteins (Le., apoA-I, E) for CE formation. Ali- 
quots of egg yolk lecithin (1500 pg) in CHC13 and 
[14C]cholesterol (35.5 pg; 5 pCi) in ethanol were dried 
under N2 and lyophilized for 1 h to remove residual sol- 
vent. Two ml of buffer was added and the sample was 
sonicated in an ice water bath for 15 min. After sonication 
the vesicle preparation was size-fractionated on a 1.6 x 
30 cm Sepharose CL-4B column equilibrated with buffer 
and running at a flow rate of 42 ml/h. Two-minute frac- 
tions were collected and elution of [ 14C]cholesterol was 
monitored by liquid scintillation spectrometry. The 
descending part of the included peak eluting from the 
column that contained small unilamellar vesicles was 
pooled, chemically analyzed (31) and used as substrate. 
The pooled vesicle fraction had a phospholipid-to- 
[ 14C]cholesterol molar ratio of 38:l. An aliquot of the vesi- 
cle preparation equivalent to 0.2 pg [ 14C]cholesterol was 
used in a LCAT assay identical to that described for 
rHDL. In some incubations, 5 pg of purified human 
350 Journal of Lipid Research Volume 36, 1995 
apoA-I was added to the incubation mixture as an ex- 
ogenous activator of LCAT. The apoA-I was added to the 
incubation tubes containing substrate vesicles, BSA, and 
buffer, and the tubes were incubated for 5 min at 37OC. 
Previous studies have shown that apoA-I binding to vesi- 
cles is very rapid and occurs within minutes after mixing 
at 25OC (32). P-Mercaptoethanol and plasma were added 
to initiate the cholesterol esterification reaction. Using the 
vesicle substrate, CE formation was linear when 1-10 pl of 
plasma was used as a source of LCAT. In addition, CE 
formation was linear from 0.5-2 h when 5 pl plasma was 
used as a source of LCAT, and the vesicle substrate choles- 
terol amount was 0.2 pg. 
Cholesteryl ester fatty acid analysis 
Plasma CE fatty acids were quantified by gas-liquid 
chromatography (33). Briefly, 100 p1 of mouse plasma was 
extracted by the method of Bligh and Dyer (30). The 
lower phase was subjected to thin-layer chromatography 
using hexane-ether-acetic acid 70:30:1 to separate CE. 
The position of the CE band was identified by spraying 
a standard lane with rhodamine B. The CE band was 
scraped and CE were eluted with 10 ml of CHC13- 
methanol 2:l. The CE were then saponified with KOH, 
the free cholesterol was extracted with hexane and dis- 
carded, the aqueous phase was acidified with 8-9 drops of 
concentrated H2S04, and the protonated free fatty acids 
were extracted into hexane. The fatty acids were then 
methylated with boron trifluoride and subjected to gas- 
liquid chromatography as described previously (33). 
Data analysis 
Data are presented as mean + standard error of the 
mean. Analysis of variance and Fisher's least significant 
difference tests were used to identify significant differ- 
ences among genotypes. 




Genotype Total Free Esterified ECRC 
mg/dl 
Normal 126 f 7" 22 * 2 105 * P 0.82 * 0.02" 
(n = 13) 
Heterozygote 89 6' 19 * 2 70 i 5h 0.78 2 0.03" 
(n = 14) 
Homozygote 45 + T 19 * 2 26 * 2' 0.58 * 0.03' 
(n = 11) 
P Value 0.0001 0.579 0.0001 0.0001 
Values are mean f SEM. P values are derived by analysis of vari- 
ance; values with unlike superscripts are significantly different (P < 0.05) 
by Fisher's least significant difference post-hoc analysis. EC, esterified 
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Fig. 1. Endogenous cholesterol esterification rate in apoA-I-deficient 
mouse plasma. Cholesterol esterification was calculated from the 
decrease in free cholesterol during a 1-h incubation of plasma at 37OC. 
Values are mean f SEM (normal = 8, heterozygote = 19, homo- 
zygote = 15). Values with unlike letters are significantly different (P < 
0.05) by analysis of variance and Fisher's least significant difference post- 
hoc analysis. 
RESULTS 
Previous studies have shown that total plasma and 
HDL cholesterol concentrations were significantly lower 
in heterozygous and homozygous apoA-I deficient mice 
compared to normal mice (24, 25). Table 1 shows the 
total, free, and esterified cholesterol concentrations in 
plasma as a function of apoA-I genotype. Total plasma 
cholesterol concentrations were significantly different 
among the three genotypes, with normal mice having the 
highest values and homozygous mice having the lowest 
values. The differences in total plasma cholesterol among 
genotypes were due entirely to differences in esterified 
cholesterol concentrations; plasma free cholesterol values 
were similar. Thus, esterified cholesterol concentrations 
were 67% and 25% of normal for heterozygotes and 
homozygotes, respectively. 
To determine the effect of apoA-I genotype on endoge- 
nous CE production, mouse plasma was incubated for 1 h 
at 37OC and the decrease in plasma free cholesterol was 
measured and used to calculate an esterification rate. 
Figure 1 shows the results of the study. Heterozygotes had 
one half the endogenous CE formation rate (20.9 * 1.5 
nmol/h per ml) of normal mice (43.9 f 2.5 nmol/h per 
ml). Homozygous mice had endogenous cholesterol es- 
terification rates that were significantly lower (4.9 f 0.9 
nmol/h per ml) than those of heterozygotes or normals. 
However, from these data it is not possible to know 
whether the decrease in cholesterol esterification was due 
to decreased plasma apoA-I (activator), LCAT (enzyme), 
or HDL (substrate). 
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Measurement of plasma cholesterol esterification rate using ex- 
ogenous rHDL substrate particles containing egg yolk phosphatidylcho- 
line, [ 1*C]cholesterol, and apoA-I (50:2:1 molar ratio). Details of assay 
conditions are given in Methods. Values are mean f SEM (n = 5 for 
each group). Values with unlike letters are significantly different 
(P < 0.05) by analysis of variance and Fisher's least significant differ- 
ence post-hoc analysis. 
An exogenous substrate particle (rHDL) containing 
phospholipid, [ W]cholesterol, and apoA-I also was used 
to measure cholesterol esterification. The results are 
shown in Fig. 2. At excess substrate concentrations (Le., 
zero order kinetics), CE formation was significantly less 
for the homozygous mice (19.2 k 1.7 nmol/h per ml; 
n = 5) compared to the normal (27.4 * 0.6 nmol/h per 
ml; n - 5) or heterozygous (28.8 f 1.3 nmol/h per ml; 
I a I  
" 
Normal Heterozygote Homozygote Homozygote 
+ apoA-I 
apoA-I Genotype 
Fig. 3. Measurement of plasma cholesterol esterification rate using ex- 
ogenous vesicle substrate particles, containing egg yolk phosphatidylcho- 
line and [l+C]cholesterol (38:l molar ratio). In some incubations 5 pg of 
human apoA-I was added to the incubation mixture as a source of ex-. 
ogenous activator protein. Details of incubation are given in Methods. 
Values are mean f SEM. Values with unlike letters are significantly 
different (P < 0.05) by analysis of variance and Fisher's least significant 
difference post-hoc analysis. 
n = 5) mice (P < 0.001). Similar results were obtained 
when initial CE formation rates were measured at lower 
substrate concentrations. Thus, even when exogenous 
human apoA-I was present in the incubation on substrate 
particles, cholesterol esterification was 30% lower for the 
homozygous mice. 
To determine the plasma cholesterol esterification rate 
with exogenous substrate but no exogenous apoA-I to 
serve as an activator for LCAT, vesicles containing phos- 
pholipid and [ l*C]cholesterol were incubated with plasma 
and cholesterol esterification was measured (Fig. 3). The 
esterification rate was identical for normal (1.63 2 0.09 
nmol/h per ml; n = 16) and heterozygous mice (1.60 * 
0.10 nmol/h per ml; n = 17), but was reduced by 60% 
(P < 0.0001) for the homozygous mice (0.64 * 0.07 
nmol/h per ml; n = 17). Addition of 5 pg of human 
apoA-I to the incubation mixture resulted in a cholesterol 
esterification rate (1.64 k 0.09 nmol/h per ml; n = 17) in- 
distinguishable from that of normal and heterozygous 
mice. 
To determine whether the decreased rate of endogenous 
cholesterol esterification in heterozygous and homozygous 
mice influenced the distribution of plasma CE species, 
plasma CE fatty acid percentage composition among 
genotypes was quantified (Table 2). Compared to normal 
and heterozygous mice, homozygous apoA-I-deficient 
mice had a significantly greater proportion of plasma CE 
fatty acids as 14:0, 16:0, 18:0, and 18:1, while the propor- 
tion of CE containing 18:2 and 20:5 n-3 was significantly 
less. CE species containing 20:4 and 22:6 n-3 averaged 
less in the homozygous mice also, but the values were not 
statistically different from those of the normal and hetero- 
zygous mice. Thus, the homozygous apoA-I-deficient 
mice had fewer CE in plasma compared to normal mice 
(Table l), and the CE species present were relatively more 
saturated. 
TABLE 2. Percentage plasma cholesteryl ester fatty acid 
composition of apoA-I-deficient mice 
ApoA-I Genotype 
CE Fatty Acid 
Normal 












6.4 f 0.7" 
1.6 f 0.2 
3.9 f 0.6" 
7 .1  f 0.2" 
51.1 f 1.0" 
15.6 f 0.5 
4.5 f 0.2" 
5.7 f 0.4 
3.7 f 0.1" 
Heterozygote 
n - 5  
% 
0.7 f 0.2" 
6.9 f 0.7" 
2.1 f 0.3 
3.8 f 0.6" 
6.5 f 0.2" 
50.3 f 1.7" 
15.4 f 1.2 
4.3 + 0.3" 
5.4 f 0.9 
4.5 f 0.3" 
Homozygote 
n - 5  P Value 
2.1 f 0.5' 
15.0 f 2.0' 
3.0 f 0.7 
12.0 f 0.8' 
14.3 f 1.5' 
27.1 f 1.8' 
11.7 f 2.0 
3.1 f 0.6' 
3.4 * 0.8 











Mean f SEM. Values with unlike letters are significantly different 
(P >0.05) by analysis of variance and Fisher's least significant difference 
post-hoc analysis. 
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DISCUSSION 
The purpose of this study was to determine the effect 
of apoA-I gene dosage on plasma CE formation. Mice 
made apoA-I deficient by gene targeting had plasma CE 
mass and endogenous CE formation rates that were pro- 
portional to apoA-I gene dosage (Table I and Fig. 1). 
Studies were designed to test whether the decrease in 
plasma CE mass and endogenous cholesterol esterifica- 
tion was the result of a decrease in apoA-I activator. Vesi- 
cle substrate particles that lacked apoA-I activator had 
cholesterol esterification rates in the plasma of homozy- 
gous mice that were 30% that of normal or heterozygous 
mice (Fig. 3). However, addition of exogenous apoA-I 
resulted in full restoration of LCAT activity. This was in 
contrast to results with apoA-I-containing rHDL, in 
which the esterification rate for homozygote plasma was 
70% of normal (Fig. 1). Taken together, these data sup- 
port the conclusion that the decreased plasma CE mass 
and cholesterol esterification rate in apoA-I-deficient mice 
was, in part, attributable to a decrease in plasma apoA-I 
mass. 
Heterozygous apoA-I-deficient mice have a sufficient 
mass of apoA-I in plasma to fully activate LCAT. CE 
production using vesicular substrate particles was the 
same for normal mice and heterozygotes, demonstrating 
that apoA-I was not limiting for the LCAT reaction in the 
plasma of heterozygous mice (Fig. 3). However, in spite 
of a normal cholesterol esterification rate with vesicle sub- 
strate particles, heterozygote mice had decreased ( - 30%) 
CE mass in plasma (Table 1) and decreased (- 50%) en- 
dogenous cholesterol esterification rates (Fig. 1). The 
most likely explanation for the data is that half the gene 
dosage of apoA-I results in a decrease of HDL substrate 
pool in plasma, leading to a decrease in plasma CE pro- 
duction by LCAT. Thus, in heterozygous mouse plasma, 
LCAT activity and apoA-I activator protein are not limit- 
ing, but HDL substrate particles likely are. These data 
suggest that half of the gene dosage of apoA-I leads to 
plasma HDL substrate depletion relative to normal mice, 
which results in decreased net plasma CE production by 
LCAT. 
Homozygous apoA-I-deficient mice have 25% of nor- 
mal CE mass plasma (Table 1) and endogenous CE pro- 
duction rates that are 10% of normal (Fig. 1). This is due 
primarily to a deficiency of apoA-I activator. Addition of 
exogenous rHDL substrate restored plasma CE produc- 
tion in homozygote mouse plasma to 70% of that in nor- 
mal plasma. Using vesicular substrate particles, CE pro- 
duction rate in homozygote mouse plasma could be fully 
restored in the presence of exogenous apoA-I, but was 
only 30% of normal in the absence of added apoA-I (Fig. 
3). It is not clear why normal CE production rates were 
observed in the plasma of homozygous mice using vesicle 
substrate particles with added apoA-I, but not with rHDL 
particles. The homozygote mice may have a slight de- 
ficiency in plasma LCAT activity relative to normal mice 
that was detected by the rHDL substrate, but not the 
vesicular substrate particles, because of the higher intrin- 
sic reactivity of rHDL with LCAT (compare rates in Figs. 
2 and 3; ref. 16). In some human apoA-I-deficient states 
LCAT activity is decreased, even when assayed with 
rHDL containing apoA-I. In these same studies plasma 
LCAT mass also was decreased (21, 22). LCAT may have 
a greater turnover rate when plasma HDL pools are de- 
creased in apoA-I deficiency, perhaps because lipoprotein- 
free LCAT is catabolized more rapidly than LCAT bound 
to HDL particles. Nonetheless, it is clear that the marked 
decrease in CE mass and esterification rate of cholesterol 
in the plasma of homozygous mice is primarily the result 
of decreased apoA-I activator protein. 
A deficiency in HDL substrate particles also is likely to 
contribute to the very low endogenous CE production 
rate (10% of normal) in the plasma of homozygous apoA- 
I-deficient mice, as addition of adequate substrate in the 
form of apoA-I-free vesicle particles resulted in CE 
production rates that were 30% of normal and addition 
of apoA-I in the presence of vesicle substrate particles re- 
stored cholesterol esterification rates to normal values. 
Therefore, the deficiency of HDL substrate particles in 
homozygous apoA-I-deficient mice seems to have less im- 
pact on endogenous CE production rates than the defi- 
ciency in apoA-I activator protein. 
The small amount of CE in the plasma of homozygous 
apoA-I-deficient mice was likely the result of liver acyl 
CoA:cholesterol acyltransferase (ACAT) activity and/or 
residual plasma LCAT activity. LCAT prefers to use poly- 
unsaturated fatty acids to generate CE, while ACAT, 
the intracellular cholesterol esterification enzyme, prefers 
monounsaturated fatty acyl groups (34-37). The plasma 
CE fatty acid profiles of homozygous mice were relatively 
enriched in saturated and monounsaturated fatty acids 
and depleted of polyunsaturated fatty acids, suggesting 
a greater contribution of hepatic ACAT to the plasma 
CE pool. The contribution of hepatic ACAT to the 
plasma CE pool increases with cholesterol feeding as 
the liver begins to accumulate CE (38, 39). How- 
ever, our data suggest that liver ACAT may contribute 
to the plasma CE pool even in chow-fed animals. Residual 
LCAT activity in the plasma of homozygous mice also 
may contribute to the plasma CE pool, as LCAT activity 
was 30% of normal for the homozygotes in the absence 
of apoA-I. The residual LCAT activity likely results 
from the ability of other apolipoproteins to activate 
LCAT, albeit not as efficiently as apoA-I (10, 17). 
We have recently shown that plasma HDL apoE content 
is greater in homozygous mice compared to heterozygous 
or normal mice (25). The increased apoE in homozygous 
mice may function to maintain a low amount of LCAT 
activity in plasma by activation of the enzyme in 
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the absence of apoA-I (40). 
It is important to emphasize the distinctions in CE 
production between the apoA-I-deficient mouse com- 
pared to human subjects deficient in apoA-I. The plasma 
esterified to total cholesterol ratio in apoA-I-difficient Ki- 
man subjects is close to normal values (Le., 0.75; refs. 22, 
41, 42), whereas homozygous apoA-I-deficient mice have 
lower values (0.587; Table 1). In addition, the endogenous 
cholesteryl ester formation rate of homozygous apoA-1- 
deficient mice is 10% of normal whereas that of apoA-1- 
deficient human subjects is 20-50% of normal (20-22). 
The reason for these differences is not clear. Notwith- 
standing these differences, the apoA-I-deficient mouse 
should prove to be a valuable animal model to pursue 
metabolic questions regarding lipoprotein metabolism in 
the absence of apoA-I. I 
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